Zunveyl, an oral medication, is a better-tolerated version of galantamine for managing mild to moderate Alzheimer's symptoms.

Dementia cases in the U.S. are expected to double by 2060, with an estimated one million people diagnosed per year, according ...

Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for ...

Groundbreaking research reveals how a cancer drug could restore brain function in early Alzheimer's patients by targeting glucose metabolism. Here's what you need to know.

Delve into the challenges Black Americans face with Alzheimer’s and the urgent need for better prevention, care, and ...

While the Alzheimer’s market is projected to experience strong growth throughout the forecast period across the 8MM, unmet ...

Recent studies implicate the immune system and a herpes virus as potential contributors to development of disease ...

Cognitive profiles for early diagnosis of Dementia with Lewy bodies (DLB) have been outlined in a new study, out today in ...

A predictive tool for determining the age at which individuals may develop mild cognitive impairment (MCI) or Alzheimer's ...